Adenocarcinoma of the Esophagogastric Junction Clinical Trial
Official title:
The Application of Fluorescence Laparoscopy in the Treatment of Adenocarcinoma of the Esophagogastric Junction
NCT number | NCT03647540 |
Other study ID # | 130020 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | August 30, 2018 |
Est. completion date | August 30, 2022 |
Verified date | April 2020 |
Source | Jilin University |
Contact | Dong Yang, Master |
714488468[@]qq.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The fluorescent laparoscopic technique would be applied to the radical resection of gastric cancer at the junction of esophagus and stomach, and compared with the traditional laparoscopic radical resection of gastric cancer to find a better surgical method for patients
Status | Recruiting |
Enrollment | 164 |
Est. completion date | August 30, 2022 |
Est. primary completion date | June 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - 1. All cases should be diagnosed as adenocarcinoma of the esophagogastric junctionncer by histology. The tumor is within 1 cm above or 2 cm below the anatomic cardia. The clinical stage is T1-3, Nx, M0 for gastric cancer which can undergo the laparoscopic surgery. 2. Eastern Cooperative Oncology Group (ECOG) scale 0-2 3. Heart, lung, liver, and kidney function can tolerate operation 4. Patients and their families are able to understand and be willing to participate in this clinical study and to sign informed consent. Exclusion Criteria: 1. history of stomach malignant disease 2. recent diagnosis of other malignant tumors (except for papillary carcinoma of the thyroid gland and basal cell carcinoma of the skin) 3. patients with obstruction, perforation, bleeding requiring emergency surgery 4. a history of abdominal surgery (which makes it difficult to perform laparoscopic procedures), severe systemic disease such as diabetes, severe chronic lung disease, cirrhosis, other malignant diseases 5. combined stomach multiple carcinomas 6. with a history of serious mental illness 7. pregnant or lactating women 8. The researchers believe that the patients are unsuitable to participate in the researchers with other cases. - |
Country | Name | City | State |
---|---|---|---|
China | the First Hospital of Jilin University | Ch'ang-ch'un | Ji Lin |
Lead Sponsor | Collaborator |
---|---|
Dong Yang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the number of the dissected lymph nodes | It includes the total number of the dissected lymph nodes and every group of lymph nodes | in the perioperative period | |
Secondary | 3-year disease-free survival | three years after operation] | ||
Secondary | the incidence of complications | one month after surgery | ||
Secondary | the operation time | The descriptive name of unit would be minute (min). | in the perioperative period | |
Secondary | the blood loss during the operation | The descriptive name of unit would be millilitre (ml). | in the perioperative period | |
Secondary | Postoperative recovery of intestinal peristalsis | The descriptive name of unit would be hour (h). | in the perioperative period | |
Secondary | cases converted to open surgery | in the perioperative period | ||
Secondary | The mean postoperative hospital stay | The descriptive name of unit would be day (d). | in the perioperative period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04062656 -
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
|
Phase 2 | |
Completed |
NCT05419349 -
Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database
|
||
Active, not recruiting |
NCT02509286 -
Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus
|
Phase 3 | |
Completed |
NCT00849615 -
Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT02287129 -
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
|
Phase 2 | |
Completed |
NCT00737373 -
Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer
|
Phase 2 |